431 results about "Oral treatment" patented technology

Oral treatment devices include a barrier layer and an oral treatment composition, and optionally an auxiliary adhesive composition, that acts as an endoskeleton so as to at least partially contribute to maintaining the barrier layer in the shape of a dental tray, or in a tray-like configuration, prior to use. The barrier layer protects the oral treatment and/or adhesive composition from saliva or moisture during use. The treatment and/or auxiliary adhesive compositions can have a consistency ranging from a sticky, viscous gel or a solid. They preferably include a tissue adhesion agent comprising a hydrophilic polymer.

A mouthpiece that adjusts manually to accommodate a broad range of different size sets of upper and lower teeth in the mouth and yet seals the treatment area from oxygen exposure. The mouthpiece includes one or more light emitters and one or more heat generators. A series of parallel texture bands are provided to guide and direct the light from the light emitters to diffuse generally evenly onto teeth to be treated. The seal arises from an inner surface of the mouthpiece tilting inwardly so that a seal bead seals in the vicinity of the gum above the teeth to be treated. Method for effecting an oral treatment such as whitening or desensitizing teeth or treating gum disease. For whitening, a whitening gel is applied to the user's teeth, the mouthpiece is then positioned in the user's mouth such that a bite surface is between upper and lower arches, a main body is between a front surface of the teeth and an inner surface of the user's lips, and a seal bead is against the user's gums. Then, the light emitter(s) and heat generator(s) are activated to effect the whitening while causing an increase in the temperature of the main body thereby enabling the user to mold the main body and conform its shape to their mouth.

A method for effecting an oral treatment of teeth and/or gums using an intra-oral device that has a mouthpiece in which is embedded a flexible circuit board and arrays of spaced apart lamps. The mouthpiece has a curvature. The lamps may be light emitting diodes that generate electromagnetic radiation, preferably in the white and blue light spectrum and the infrared and ultraviolet light spectrum. The arrays are positioned to expose the facial and lingual sides of the teeth and/or gums for effecting the treatment when the mouthpiece is positioned to fit upper and lower rows of teeth within accommodating recesses. The flexible circuit board is flexed to exhibit a curvature that follows a curvature of the mouthpiece. Treatments include whitening teeth, desensitizing teeth, and treating gums to prevent periodontal disease.

A mouthpiece that adjusts manually to accommodate a broad range of different size sets of upper and lower teeth in the mouth and yet seals the treatment area from oxygen exposure. The mouthpiece includes light emitting diodes and heat generating resistors all arranged in an array. A series of parallel texture bands are provides to guide and direct the light from the LEDs to diffuse generally evenly onto teeth to be treated. The seal arises from an inner surface of the mouthpiece tilting inwardly so that a seal bead seals in the vicinity of the gum above the teeth to be treated.

A medical oral treatment face mask includes a mask body and a band set. The mask body includes a water-repellent layer, an isolation layer and a water-absorbent layer. The isolation layer, which along with the water-repellent layer has a corresponding opening. The water-absorbent layer is arranged between the water-repellent layer and the isolation layer. The band set is fixed on two sides of the mask body.

An oral treatment device that emits light onto surfaces of a user's teeth. In one aspect, the oral treatment device includes an intraoral mouthpiece. The mouthpiece comprises: a first light emitting surface configured to emit light onto a user's maxillary teeth, the first light emitting surface having a concave curvature; a second light emitting surface configured to emit light onto a user's mandibular teeth, the second light emitting surface having a concave curvature; the first and second light emitting surface located on opposite sides of a horizontal reference plane; the first light emitting surface inclined so that a first acute angle is formed between with the first light emitting surface and the horizontal reference plane; and the second light emitting surface inclined so that a second acute angle is formed between with the second light emitting surface and the horizontal reference plane.

A method of oral treatment comprises passing a flow of a gas mixture from a pressure vessel containing the gas mixture through a generator of non-thermal plasma; applying a partially ionising electrical potential to the flow of the gas mixture in the plasma generator, and thereby forming a non-thermal gaseous plasma in the gas mixture, and causing the flow of the gas mixture downstream of the plasma generator to perform the oral treatment. The gas mixture comprises (a) a noble gas selected from helium and argon and mixtures thereof, and (b) an additive gas selected from water vapour, air, oxygen, nitrogen, hydrogen, carbon monoxide, carbon dioxide, nitrous oxide and nitric oxide and mixtures of any two or more thereof. The additive gas forms up to 1% by volume of the gas mixture. The oral treatment may be the cosmetic whitening of teeth, the non-clinical cleaning of teeth or the in situ cleaning of orthodontic braces, amongst others.

The present invention provides a low-cost system and method for detecting substances within a mouth that influence oral health. The system and method also treat the mouth when certain substances are detected within the mouth. In some forms, the system includes a holder, a sensor that is attached to the holder and an oral treatment that is secured by the holder. The sensor detects a substance that influences oral health when the system is placed near a mouth. The oral treatment engages the mouth to treat the mouth when the substance is detected within the mouth. The method includes placing the system near a mouth and detecting the presence of a substance that influences oral health using the sensor. The method further includes treating the mouth using the oral treatment.

An oral treatment device that emits light onto surfaces of a user's teeth. In one aspect, the oral treatment device includes an intraoral mouthpiece. The mouthpiece comprises a lamp support structure comprising a lamp support surface and is formed of a first material. A flexible lamp is mounted to the lamp support surface so that a light emitting surface of the flexible lamp assumes a concave curvature, thereby forming a lamp assembly. A guard component is overmolded to the lamp assembly. The guard component is formed of an elastomeric material having a hardness that is less than a hardness of the first material. In one embodiment, the oral treatment device may be a teeth whitening device.

Oral treatment devices formed from wax-based compositions that are thermally stable when formed into a three-dimensional shape to a temperature of at least 45° C. and plastically deformable at room temperature (25° C.). The wax-based compositions include a wax fraction homogeneously blended with a polymer fraction. The wax fraction includes at least one wax. The polymer fraction includes at least one polymer selected such that, when the wax and polymer are homogeneously blended together, they yield a wax-based composition having the desired properties of thermal stability and plastic deformability. Oral treatment devices are dimensionally stable to a temperature of at least 40° C. without external support and can be plastically deformed in a user's mouth to become at least partially customized to the size and shape of user's unique dentition and/or an appliance in a user's mouth.

The present, invention provides an oral delivery system for a therapeutic compound that is an acid, a salt of an acid or an unionized compound or a proactive form thereof with pharmacological, physiological or biochemical activity. The present invention particularly provides a swallow formulation comprising a therapeutic compound that is an acid, a salt of an acid or an unionized compound or a proactive form thereof which facilitates the rapid delivery of the therapeutic compound to the circulatory system.

Treatment devices in the shape of a dental tray, strip or patch include a barrier layer and a protective adhesive composition. Treatment kits include one or more treatment devices and one or more treatment compositions that are initially separate from the treatment devices. The treatment compositions may be contained within a syringe (e.g., a unit dose syringe) for ease of delivery. The treatment composition is dispensed from the syringe onto the barrier layer and then placed over a person's teeth and/or gums. The protective adhesive composition, in combination with the barrier layer, at least partially confines the treatment composition to a desired location within the person's mouth during use. The barrier layer protects the treatment and protective adhesive compositions from saliva or moisture found in the person's mouth.

The invention discloses lactobacillus rhamnosus. A strain (lactobacillus rhamnosus) LR863 is preserved in China General Microbiological Culture Collection Center (CGMCC) and the preservation number isCGMCC No. 14410. The lactobacillus rhamnosus disclosed by the invention has remarkable bacterium-inhibition and sterilization effects on oral pathogenic microorganisms including streptococcus mutans,streptococcus gordonii, porphyromonas gingivalis, fusobacterium nucleatum, actinobacillus actinomycetemcomitans and the like, and has the effects of reducing formation of dental plaque and reducing occurrence and development of oral diseases including tooth decay, periodontitis and the like. A lactobacillus rhamnosus preparation disclosed by the invention can comprise viable bacterium thalli of the lactobacillus rhamnosus, dead bacterium thalli of the lactobacillus rhamnosus, metabolic products of the lactobacillus rhamnosus and intracellular extract, is an oral probiotics preparation which has wide application and a remarkable effect, and can be widely used as an additive of liquid-state foods, solid-state foods, colloidal foods, oral hygiene products and oral treatment drugs.

The present invention relates generally to therapeutic formulations. More particularly, this present invention provides an oral delivery system for a therapeutic compound that is a base, a salt of a base or an amphoteric compound or a salt of a amphoteric compound with pharmacological, physiological or biochemical activity or a proactive form thereof. The present invention even more particularly provides a swallow formulation comprising a therapeutic compound that is a base, a salt of a base, an amphoteric compound or a salt of an amphoteric compound which facilitates the rapid delivery of the therapeutic compound to the circulatory system.

Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

An oral treatment device that includes a mouthpiece and an electromagnetic radiation source. In one aspect, the oral treatment device includes a mouthpiece comprising a curved wall having a concave inner surface and a bite platform extending from the concave inner surface of the curved wall to a distal end, the distal end of the bite platform extending continuously in a non-interrupted manner from a first end of the bite platform to a second end of the bite platform; an electromagnetic radiation source configured to emit electromagnetic radiation from the curved wall; and wherein the bite platform comprises a collapsible region such that the mouthpiece is alterable between: (1) a biased state in which the curved wall has a first curvature; and (2) a flexed state in which the curved wall has a second curvature that is different than the first curvature.

Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

In the present invention there is provided a pharmaceutical composition for oral administration which comprises bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient and which shows a dissolution of the bendamustine of at least 60% in 20 minutes, 70% in 40 minutes and 80% in 60 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5, and wherein the pharmaceutically acceptable excipient is either a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of a polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide or a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5. The invention further relates to the above pharmaceutical composition for use for the oral treatment of a medical condition which is selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia, acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer and non-small cell lung cancer. The invention moreover relates to the above pharmaceutical composition for the above use wherein the dosage regimen comprises at least the administration of a dose of 100 to 600 mg/m2/per person of bendamustine on day 1 and day 2, optionally a dose of 50 to 150 mg/m² i.v. or orally of a corticosteroid on days 1 to 5, and optionally a suitable dose of a further active agent selected from the group consisting of an antibody specific for CD20, an anthracyclin derivative, a vinca alkaloid or a platin derivative; and the repetition of said dosage regimen 4 to 15 times after intervals of two to four weeks.

The invention relates to methods of measuring the overall elasticity of skin and determining the portion of the overall elasticity that is due to elastic properties and the portion of overall elasticity that is due to viscoelastic properties of the skin and correlating the results of the measurement to an individual's chronological age. The invention also relates to methods of measuring improvements in a person's skin health by measuring elasticity before, during and after human clinical trials of topical and/or oral treatment compositions. The parameters for determining elasticity are based on areas that are defined on a deformation/relaxation curve and require that an inflection point be determined for each skin sample analyzed.